Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of acute or chronic dysfunction of cardiac muscle. The method may employ a kit which includes a platelet-rich plasma composition and a pH adjusting agent and a catheter or syringe for delivery of the platelet-rich plasma composition to dysfunctional cardiac muscle. The kit may also include a syringe for withdrawing blood from a patient and a centrifuge device means to obtain platelet-rich plasma.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a cancer in a variety of tissues. Particularly, treatment of brain cancer with platelet releasate is described.

Abstract: Kits are described for the treatment of acute or chronic dysfunction of cardiac muscle. The kit includes a platelet-rich plasma composition with a pH adjusting agent and a catheter or syringe for delivery of the platelet-rich plasma composition to dysfunctional cardiac muscle. The kit may also include a syringe for withdrawing blood from a patient and a centrifuge device to obtain platelet-rich plasma.

Abstract: Methods of producing neutrophil-depleted platelet-rich plasma by passing a blood, platelet or platelet-rich plasma fraction through a narrow, twisted and/or charged environment to remove neutrophils and produce neutrophil-depleted platelet-rich plasma is described. The neutrophil-depleted platelet-rich plasma may be depleted in neutrophils by 75% or more and includes at least 0.5×106 platelets per ml. The pH of the neutrophil-depleted platelet-rich plasma may be adjusted to 7.3-7.5.

Abstract: Methods of producing neutrophil-depleted platelet-rich plasma by passing a blood, platelet or platelet-rich plasma fraction through a narrow, twisted and/or charged environment to remove neutrophils and produce neutrophil-depleted platelet-rich plasma is described. The neutrophil-depleted platelet-rich plasma may be depleted in neutrophils by 75% or more and includes at least 0.5×106 platelets per ml. The pH of the neutrophil-depleted platelet-rich plasma may be adjusted to 7.3-7.5.

Abstract: Treatment methods are disclosed for psychiatric and neurodegenerative disorders by treatment of the patient with platelet-rich plasma (PRP). PRP is administered to areas of the brain that have been identified as associated with the psychiatric or neurodegenerative disorder to replenish the dysfunctional tissue.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of peripheral vascular disease. A platelet-rich plasma composition is introduced into the muscle or soft tissue in the area of hypovascularity to treat the peripheral vascular disease.

Abstract: A method of delivering a bioactive composition to the right side of the heart is described. The method can be used to treat cardiac dysfunction such as myocardial infarction, arrhythmias or congestive heart failure. A dual lumen catheter is described for delivering the bioactive substance by inserting a first cannula of a dual lumen catheter into a vein to access the right ventricle. The first cannula has a first balloon which is blown up proximal to the tricuspid valve. A second cannula is then introduced which accesses the right side of the heart and coronary sinus. The bioactive substance is then delivered to the right side of the heart. The bioactive substance may include platelets and/or white blood cells at concentrations higher than what is normally found in whole blood.

Abstract: Platelets are concentrated from the blood of a patient. The platelets are treated by a method such as ultrasound or agitation to obtain platelet releasate. This releasate as a whole or a component thereof is formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer.

Abstract: A blood component such as platelets is concentrated. The concentrate, such as platelet-rich plasma, is used in a cell culture medium to grow and proliferate cells. The cells may be from the same person from which the blood concentrate is obtained. The cells grown in the culture medium may be used to treat a patient which may be the same patient from which the blood was extracted and/or the cells were obtained.

Abstract: Platelets are concentrated from the blood of a patient. The platelets are treated by a method such as ultrasound or agitation to obtain platelet releasate. This releasate as a whole or a component thereof is formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer.

Abstract: Treatment methods are disclosed for psychiatric and neurodegenerative disorders by treatment of the patient with platelet-rich plasma (PRP). PRP is administered to areas of the brain that have been identified as associated with the psychiatric or neurodegenerative disorder to replenish the dysfunctional tissue.

Abstract: Methods and kits are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. The kit includes components for the preparation of platelet-rich plasma from the patient's blood and components for administration to an area in need of vascularization. The methods and kits are useful for the treatment of tendinosis, and in particular, lateral epicondylitis and plantar fasciitis.

Abstract: A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted.

Abstract: A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is described.

Abstract: Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. The methods are useful for vascularizing tissue with a compromised blood supply, particularly cardiac tissue with a compromised blood supply due to heart attack or congestive heart failure.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to cardiac muscle for treatment of chronic dysfunction of cardiac muscle is disclosed.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is disclosed.

Abstract: Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. In particular, a method of treating a cardiac tissue lesion is disclosed.